You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME / ABIM MOC / CE

Can Mouthwash Curb Growth of Gonorrhea?

  • Authors: News Author: Laird Harrison
    CME Author: Charles P. Vega, MD
  • CME / ABIM MOC / CE Released: 1/26/2017
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 1/26/2018
Start Activity


Target Audience and Goal Statement

This article is intended for primary care clinicians, infectious disease specialists, emergency medicine specialists, nurses, pharmacists, and other clinicians who care for patients at risk for oropharyngeal gonorrhea.

The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  1. Assess the efficacy of an antiseptic mouthwash in promoting better oral health
  2. Evaluate the efficacy of an antiseptic mouthwash in the management of oropharyngeal gonorrhea


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Laird Harrison

    Freelance writer, Medscape

    Disclosures

    Disclosure: Laird Harrison has disclosed no relevant financial relationships.

Editor(s)

  • Robert Morris, PharmD

    Associate CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed no relevant financial relationships.

CME Author(s)

  • Charles P. Vega, MD

    Health Sciences Clinical Professor of Family Medicine, University of California, Irvine, School of Medicine, Irvine, California

    Disclosures

    Disclosure: Charles P. Vega, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Allergan, Inc.; McNeil Consumer Healthcare
    Served as a speaker or a member of a speakers bureau for: Shire 

CME Reviewer/Nurse Planner

  • Amy Bernard, MS, BSN, RN-BC

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.


Accreditation Statements


Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    This Enduring Material activity, Medscape Education Clinical Briefs, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Term of approval begins 9/1/2016. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Approved for 0.25 AAFP Prescribed credits.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    AAFP Accreditation Questions

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number 0461-0000-17-013-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

 There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Can Mouthwash Curb Growth of Gonorrhea?

Authors: News Author: Laird Harrison CME Author: Charles P. Vega, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC / CE Released: 1/26/2017

Valid for credit through: 1/26/2018

processing....

Clinical Context

Mouthwash is rarely considered as a potential asset against disease, but certain rinses have been recognized for many years for improving oral health. According to a review by Ross and colleagues, which appeared in the spring 1989 issue of the Journal of Clinical Dentistry, [1] Listerine (Johnson & Johnson Consumer Inc) safely improves oral health. In 4 clinical trials lasting 6 months or longer, Listerine was effective in reducing both supragingival plaque and gingivitis. In addition, 2 microbiology studies found no development of resistant microorganisms or other presumptive oral pathogens among Listerine users.

The prevalence of gonorrhea has increased among men who have sex with men (MSM). The authors of the current study believe that rates of gonorrhea may increase further as the threat of HIV infection decreases with wider use of preexposure prophylaxis. Therefore, simple interventions that can prevent the spread of gonorrhea and antimicrobial resistance of gonorrhea are critically important. The current research by Chow and colleagues combines an in vitro study with a small clinical trial to evaluate whether Listerine may be effective against gonorrhea.

Study Synopsis and Perspective

Listerine mouthwash inhibits the growth of oral gonorrhea bacteria in the mouth, a new study has found.

In a randomized trial, 52% (95% confidence interval [CI], 34%-69%), of the pharyngeal surfaces of men who rinsed and gargled with the mouthwash for 1 minute tested positive for Neisseria gonorrhoeae compared with 84% (95% CI, 64%-95%) of the pharyngeal surfaces of men who rinsed and gargled with a saline solution.

"With daily use it may increase gonococcal clearance and have important implications for prevention strategies," Eric P.F. Chow, PhD, from the Melbourne Sexual Health Centre in Melbourne, Australia, and colleagues write in an article published online December 20 in Sexually Transmitted Infections.[2]

Gonorrhea infections among men are increasing in many countries as condom use declines, mostly among MSM, the researchers explain.

In Australia, new diagnoses doubled from 6892 to 11,508 in the last 5 years, with 70% of these infections in MSM, the researchers write.

As the incidence of the infections rises, so do concerns about the risk for antibiotic resistance, highlighting the need for new preventive measures, they say.

As early as 1879, well before the advent of antibiotics, the maker of Listerine claimed it could be used to cure gonorrhea. Until now, however, no published research has tested this claim.

To fill that gap, Dr Chow and colleagues assessed whether the mouthwash could curb the growth of N gonorrhoeae in laboratory tests and in a clinical trial of MSM.

In the laboratory tests, the researchers applied various dilutions up to 1:32 of Listerine Cool Mint and Total Care to cultures of N gonorrhoeae to see which, if any, of them might curb growth of the bacteria. Both formulations contain 21.6% alcohol. The authors also applied a saline solution to an identical set of cultures.

Listerine at dilutions up to 1 in 4, applied for 1 minute, significantly reduced the number of N gonorrhoeae on the culture plates. The saline solution had no effect.

Encouraged, the researchers undertook a clinical trial, starting with 196 MSM who had tested positive for gonorrhea in their mouths or throats and were returning for treatment at Melbourne Sexual Health Centre between May 2015 and February 2016.

At this return visit, 58 of the men once again tested positive for the bacteria on their pharynxes. The median age of these men was 27 years. They had had a median of 6 sexual partners in the previous 3 months.

The researchers assigned 33 men to rinse and gargle for 1 minute with the mouthwash, and 25 to rinse and gargle with a saline solution for 1 minute.

The researchers then retested the men and found that those in the mouthwash group were 80% less likely to test positive for gonorrhea on their pharyngeal surface compared with the other men (odds ratio [OR], 0.20; 95% CI, 0.07-0.72).

In a similar manner, of the men who gargled and rinsed with the mouthwash, 57% (95% CI, 34%-77%) tested positive for gonorrhea at the tonsillar fossae compared with 90% (95% CI, 68%-99%) of those in the saline group (P =.016).

Men in the mouthwash group were 86% less likely to test positive on this surface than were men in the saline group (OR, 0.14; 95% CI, 0.03-0.77).

Of the men in the mouthwash group, 57% (95% CI, 34%-77%) had infection on the posterior oropharynx compared with 70% (95% CI, 46%-88%) of those in the saline group.

Although the difference between groups in pharyngeal surface infections was statistically significant (P =.013), as was the difference in tonsillar fossae infections (P =.016), the difference in posterior oropharynx infections was not (P =.277).

The researchers acknowledge that the follow-up time in the study was short, so it is possible that the effects of the mouthwash might be short lived. However, the laboratory test results suggest a longer-term effect, they reason.

Whether an oral mouthwash can reduce gonorrhea infections of the anus and urethra remains to be seen. Some studies have suggested that pharyngeal gonorrhea spreads to the anus and urethra, the researchers note.

As people are less likely to have symptoms from oral gonorrhea infections, they are less likely to receive treatment rapidly than with urethral infections, the researchers point out.

A larger trial is currently underway to confirm the results of this study and see whether the use of mouthwash could curb the spread of gonorrhea, according to a news release from the journal.

The Australian National Health and Medical Research Council funded the study. The researchers have disclosed no relevant financial relationships.

Sex Transm Infect. Published online December 20, 2016.

Study Highlights

  • For the in vitrostudy, researchers evaluated Listerine Cool Mint and Total Care products. They applied an aliquot of one of these Listerine products or phosphate-buffered saline (control) to an agar plate containing 108 colony-forming units/mL of a pharyngeal isolate of N gonorrhoeae.
  • The main result of this part of the research protocol was inhibition of N gonorrhoeae through 48 hours of observation.
  • The clinical trial of Listerine took place at a large medical center in Australia. This center instituted a program of screening MSM for oropharyngeal gonorrhea. Men with a positive result who returned for the treatment of gonorrhea could participate in the Listerine trial. Only men 16 years or older were eligible for study participation.
  • Men with urethral gonorrhea were excluded from participation in the trial.
  • Participants were randomly assigned to gargle for 1 minute with 20 mL of Listerine Cool Mint or gargle with saline solution.
  • Pharyngeal swabs were collected immediately before and 5 minutes after the gargling exercise. The main study outcome was the growth of N gonorrhoeae on GC agar before and after the gargle exercise.
  • In the in vitro study, Listerine inhibited the growth of gonorrhea, whereas the saline solution did not.
  • 196 men agreed to participate in the clinical trial, and 58 men tested positive on culture at the time of random selection. The median age of participants was 27 years, and 21% of participants used mouthwash daily. 9% of participants were HIV positive.
  • There were no significant differences in baseline characteristics in comparing the Listerine group vs the saline group.
  • After gargling was completed, the OR for a positive gonorrhea culture result at the pharyngeal surface was 0.20 (95% CI, 0.07-0.72) in comparing the Listerine group vs the saline group. The respective OR for a positive culture result at the tonsillar fossae was 0.14 (95% CI, 0.03-0.77).
  • There was no significant difference between treatment groups in the rate of positive culture results at the posterior oropharynx after gargling.
  • Overall, the rates of a positive culture result for gonorrhea after gargling were 52% in the Listerine group and 84% in the saline group.

Clinical Implications

  • Listerine mouthwash can reduce supragingival plaque and gingivitis. In addition, 2 microbiology studies found no development of resistant microorganisms or other presumptive oral pathogens among Listerine users.
  • In the current study by Chow and colleagues, Listerine mouthwash was inhibitory against N gonorrhoeae cultures in the laboratory and was more effective than saline in promoting negative oropharyngeal culture results for gonorrhea immediately after gargling.
  • Implications for the Healthcare Team: The current study suggests that Listerine mouthwash may be effective in the prevention and treatment of oropharyngeal gonorrhea. Listerine has a low risk for adverse effects and is inexpensive, and it may be recommended to individuals at high risk for oropharyngeal gonorrhea. However, further testing is needed before broader recommendations may be made.

CME Test